The anti-PD-L1 drug significantly extended survival in NSCLC patients with high PD-L1 expression compared to docetaxel, while alectinib shrank tumors for those with ALK-positive tumors and brain metastases.
The American Society of Clinical Oncology held its annual meeting May 30 to June 3 in Chicago. The following are abstracts presented at the meeting focused on genomically- informed treatment strategies.
CHICAGO (GenomeWeb News) – Researchers are tracking down genetic variants that they hope will help identify childhood cancer patients at increased risk of treatment-related health complications later in life, City of Hope researcher Smita Bhatia reported at the annual American Society of Clinical
Researchers affiliated with breast cancer charity the Side-Out Foundation presented pilot study data this week at the American Society of Clinical Oncology's annual meeting suggesting proteomics' potential as a tool in personalizing therapy for breast cancer.